Page last updated: 2024-08-23

cabergoline and Local Neoplasm Recurrence

cabergoline has been researched along with Local Neoplasm Recurrence in 21 studies

Research

Studies (21)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (23.81)	29.6817
2010's	8 (38.10)	24.3611
2020's	8 (38.10)	2.80

Authors

Authors	Studies
Chen, S; Dong, J; Gu, J; Jiang, X; Li, D; Wen, X; Zou, Y	1
Borhan, MK; Tan, FHS	1
Leshchenko, OY	1
Berberoğlu, M; Bilici, E; Ceran, A; Kontbay, T; Özsu, E; Şıklar, Z; Uyanık, R	1
Espinosa-Cárdenas, E; Mendoza-Zubieta, V; Mercado, M; Ramírez-Rentería, C; Sánchez-García, M; Sosa-Eroza, E	1
Ahn, SS; Kim, D; Kim, EH; Kim, K; Ku, CR; Lee, EJ; Moon, JH; Park, YW	1
Astafyeva, LI; Kadashev, BA; Kalinin, PL; Melnichenko, GA; Sharipov, OI; Shishkina, LV; Sidneva, JG	1
Bronstein, MD; Greenman, Y	1
Bilbao, I; Egaña, N; García, C; Olaizola, I	1
Ikeda, H; Tominaga, T; Watanabe, K; Yoshimoto, T	1
Couldwell, WT; Eloy, JA; Liu, JK; Wong, A	1
Arduç, A; Berker, D; Doğan, BA; Güler, S; Işık, S; Nasıroğlu, NI; Tuna, MM	1
Dogansen, SC; Selcukbiricik, OS; Tanrikulu, S; Yarman, S	1
Bellaviti Buttoni, P; Carosi, G; Ferrante, E; Filopanti, M; Malchiodi, E; Mantovani, G; Profka, E; Rodari, G; Sala, E; Spada, A; Verrua, E	1
Ahmad, MS; Nakhleh, A; Pearl, IW; Reut, M; Saiegh, L; Shechner, C	1
Arda, N; Comlekci, A; Men, S; Yener, S; Yesil, S	1
Courtney, HC; Hunter, SJ; Johnston, PC; Mc Cance, DR	1
Chang, JY; Kattah, JC; Orth, EH; Talkad, AV; Xu, MY	1
Werner, S	1
Beckers, A; Bloch, B; Kalife, A; Petrossians, P; Ronci, N; Stevenaert, A; Tabarin, A; Valdés Socin, H	1
Agostini, S; Billeci, D; Conte, N; De Menis, E; Marton, E; Tramontin, P; Visentin, A	1

Reviews

2 review(s) available for cabergoline and Local Neoplasm Recurrence

Article	Year
The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis. BMC endocrine disorders, 2021, Nov-13, Volume: 21, Issue:1 Topics: Bromocriptine; Cabergoline; Deprescriptions; Dopamine Agonists; Humans; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactinoma	2021
Update on prolactinomas. Part 2: Treatment and management strategies. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2015, Volume: 22, Issue:10 Topics: Bromocriptine; Cabergoline; Disease Management; Dopamine Agonists; Drug Administration Schedule; Drug Resistance, Neoplasm; Ergolines; Female; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Neuroendoscopy; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactin; Prolactinoma; Radiosurgery; Sphenoid Sinus	2015

Article

Year

The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis.

BMC endocrine disorders, 2021, Nov-13, Volume: 21, Issue:1

Topics: Bromocriptine; Cabergoline; Deprescriptions; Dopamine Agonists; Humans; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactinoma

2021

Update on prolactinomas. Part 2: Treatment and management strategies.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2015, Volume: 22, Issue:10

Topics: Bromocriptine; Cabergoline; Disease Management; Dopamine Agonists; Drug Administration Schedule; Drug Resistance, Neoplasm; Ergolines; Female; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Neuroendoscopy; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactin; Prolactinoma; Radiosurgery; Sphenoid Sinus

2015

Other Studies

19 other study(ies) available for cabergoline and Local Neoplasm Recurrence

Article	Year
Aggressive giant prolactinoma: a case report. Journal of medical case reports, 2022, Apr-30, Volume: 16, Issue:1 Topics: Adolescent; Adult; Cabergoline; Female; Humans; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma; Temozolomide; Young Adult	2022
[Hyperprolactinemia in the postmenopause: versions and contraversions]. Terapevticheskii arkhiv, 2021, Oct-15, Volume: 93, Issue:10 Topics: Cabergoline; Dopamine Agonists; Estrogens; Female; Humans; Hyperprolactinemia; Neoplasm Recurrence, Local; Pituitary Neoplasms; Postmenopause; Progestins; Prolactin; Prolactinoma	2021
Hyperprolactinemia in children and adolescents and longterm follow-up results of prolactinoma cases: a single-centre experience. The Turkish journal of pediatrics, 2022, Volume: 64, Issue:5 Topics: Adolescent; Cabergoline; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Hyperprolactinemia; Infant; Male; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies	2022
High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment? Endocrine, 2020, Volume: 70, Issue:1 Topics: Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma	2020
Biochemical Remission after Cabergoline Withdrawal in Hyperprolactinemic Patients with Visible Remnant Pituitary Adenoma. The Journal of clinical endocrinology and metabolism, 2021, 01-23, Volume: 106, Issue:2 Topics: Adolescent; Adult; Biomarkers, Pharmacological; Biomarkers, Tumor; Cabergoline; Cohort Studies; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm, Residual; Pituitary Neoplasms; Prolactinoma; Remission Induction; Republic of Korea; Retrospective Studies; Treatment Outcome; Withholding Treatment; Young Adult	2021
[Changes in the morphological structure of giant prolactinoma during treatment with cabergoline]. Problemy endokrinologii, 2020, 09-16, Volume: 66, Issue:3 Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Humans; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactinoma	2020
Cabergoline should be attempted in progressing non-functioning pituitary macroadenoma. European journal of endocrinology, 2021, Aug-27, Volume: 185, Issue:4 Topics: Adenoma; Cabergoline; Chemotherapy, Adjuvant; Disease Progression; Humans; Neoplasm Recurrence, Local; Neoplasm, Residual; Neurosurgical Procedures; Patient Selection; Pituitary Neoplasms; Practice Patterns, Physicians'; Tumor Burden	2021
Failure of a second temozolomide cycle in a patient with a prolactin-secreting pituitary carcinoma. Endocrinologia, diabetes y nutricion, 2017, Volume: 64, Issue:10 Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bromocriptine; Cabergoline; Combined Modality Therapy; Dacarbazine; Drug Substitution; Ergolines; Fatal Outcome; Headache; Humans; Hyperprolactinemia; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma; Proton Therapy; Temozolomide	2017
Transsphenoidal microsurgical results of female patients with prolactinomas. Clinical neurology and neurosurgery, 2013, Volume: 115, Issue:9 Topics: Adult; Cabergoline; Cavernous Sinus; Dopamine Agonists; Endoscopy; Ergolines; Female; Humans; Magnetic Resonance Imaging; Microsurgery; Neoplasm Recurrence, Local; Neurosurgical Procedures; Pituitary Neoplasms; Postoperative Complications; Pregnancy; Prolactin; Prolactinoma; Retrospective Studies; Sphenoid Bone; Treatment Outcome	2013
Evaluation of atherosclerosis after cessation of cabergoline therapy in patients with prolactinoma. Anatolian journal of cardiology, 2016, Volume: 16, Issue:6 Topics: Adolescent; Adult; Atherosclerosis; Brachial Artery; Cabergoline; Carotid Intima-Media Thickness; Cross-Sectional Studies; Ergolines; Female; Humans; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma; Prospective Studies; Young Adult	2016
Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when? Pituitary, 2016, Volume: 19, Issue:3 Topics: Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Deprescriptions; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Neoplasm Recurrence, Local; Patient Selection; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Time Factors; Tumor Burden; Young Adult	2016
Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas. Journal of endocrinological investigation, 2016, Volume: 39, Issue:12 Topics: Adult; Aged; Biomarkers; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prognosis; Prolactinoma; Tomography, X-Ray Computed; Withholding Treatment	2016
Cabergoline treatment for recurrent Cushing's disease during pregnancy. Hormones (Athens, Greece), 2016, Volume: 15, Issue:3 Topics: Adult; Antineoplastic Agents; Biomarkers; Cabergoline; Ergolines; Female; Humans; Hydrocortisone; Live Birth; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Neoplasm, Residual; Pituitary ACTH Hypersecretion; Pregnancy; Pregnancy Complications; Remission Induction; Treatment Outcome	2016
Misdiagnosis due to the hook effect in prolactin assay. Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2008, Volume: 17, Issue:5 Topics: Antineoplastic Agents; Cabergoline; Diabetes Insipidus, Neurogenic; Diagnostic Errors; Ergolines; Female; Glucocorticoids; Humans; Hypopituitarism; Middle Aged; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prednisolone; Prolactin; Prolactinoma; Thyroxine	2008
Macroprolactinomas presenting as nasal polyps: a series of three cases. Irish journal of medical science, 2012, Volume: 181, Issue:2 Topics: Adult; Antineoplastic Agents; Cabergoline; Diagnosis, Differential; Diagnostic Errors; Ergolines; Humans; Male; Middle Aged; Nasal Polyps; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin	2012
Prolactinoma presenting as painful postganglionic Horner syndrome. Neurology, 2004, Apr-27, Volume: 62, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Bromocriptine; Cabergoline; Carotid Arteries; Dopamine Agonists; Ergolines; Horner Syndrome; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Migraine Disorders; Neoplasm Recurrence, Local; p-Hydroxyamphetamine; Pituitary Neoplasms; Prolactin; Prolactinoma; Remission Induction	2004
[Recurrence of prolactinoma surveyed. Hormone therapy can safely be withdrawn for a long time in patients with normalized prolactin levels and invisible tumor]. Lakartidningen, 2004, Oct-07, Volume: 101, Issue:41 Topics: Antineoplastic Agents; Cabergoline; Dopamine Agonists; Ergolines; Humans; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma	2004
ACTH silent adenoma shrinking under cabergoline. European journal of endocrinology, 2001, Volume: 144, Issue:1 Topics: Adenoma; Adrenocorticotropic Hormone; Aged; Antineoplastic Agents; Autoradiography; Cabergoline; Ergolines; Humans; In Situ Hybridization; Male; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactinoma; Receptors, Dopamine D2; RNA, Messenger	2001
Pituitary adenomas in childhood and adolescence. Clinical analysis of 10 cases. Journal of endocrinological investigation, 2001, Volume: 24, Issue:2 Topics: Acromegaly; Adenoma; Adolescent; Amenorrhea; Bromocriptine; Cabergoline; Child; Ergolines; Female; Headache; Human Growth Hormone; Humans; Male; Neoplasm Recurrence, Local; Octreotide; Pituitary Neoplasms; Prolactinoma; Puberty, Delayed; Radiotherapy; Treatment Outcome; Vision Disorders; Visual Fields	2001